Project Grant K99HL173668
Award Date
9/9/24
Completion Date
8/31/26
Dollars Obligated
$118K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55454, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $699,133 to the University of California, Los Angeles (UCLA) to conduct research on the epigenetic regulation of heart failure with preserved ejection fraction (HFPEF). The goal is to reveal molecular insights into the actions of SGLT2 inhibitors and GLP1 agonists across the heart, kidney, and liver in a rat model of HFPEF. The research...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate a potential mechanism underlying heart failure with preserved ejection fraction (HFpEF). The $126,387 award to The Johns Hopkins University aims to determine how reduced activation of the translation factor eIF5A, through a process called hypusination, impairs the translation of genes involved in ubiquitination and protein quality...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding a randomized controlled trial to evaluate the effectiveness of gamification and social incentives in increasing adherence to physical activity recommendations among patients with heart failure with preserved ejection fraction (HFPEF). The 5-year, $809,029 award will support a 3-arm trial to assess whether interventions using...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $500,089.80 to the University of Pittsburgh to investigate the role of macrophages in heart failure with preserved ejection fraction (HFPEF). The research aims to uncover the mechanisms by which inflammatory macrophages cause cardiac remodeling in HFPEF at the cellular, molecular, and functional levels. Specifically, the project will investigate how inflammatory...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Miami University supports research examining the interactive roles of cardiorespiratory fitness and adiposity on the recovery of impaired glucose and vascular control after a period of physical inactivity. The $422,894 award, effective from Apr 20, 2025 to Mar 31, 2028, will fund a study to investigate how existing health status impacts the recovery of impaired glucose...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $777,258 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Beth Israel Deaconess Medical Center, Inc. (BIDMC) on February 25, 2025. The grant's objective is to "UNRAVEL THE MECHANISM OF HEART FAILURE IN HYPERTROPHIC CARDIOMYOPATHY WITH EXERCISE CMR", leveraging advanced cardiac magnetic resonance imaging (CMR) techniques to better characterize the pathophysiology of heart failure in hypertrophic...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will provide $374,592 to the University of Rochester to conduct a research study on electronically-delivered home rehabilitation programs for patients who have experienced acute pulmonary embolism. The study aims to evaluate whether a prescriptive exercise program with heart rate monitoring is more effective than regular electronic contact in reducing post-pulmonary embolism...
This $625,835 federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to optimize aerobic fitness and functional response to exercise in older adults. The grant aims to test the efficacy of a combined high-intensity interval training (HIIT) and high-intensity resistance training (HIRT) approach to improve peak oxygen uptake (VO2peak) and physical function in patients eligible for cardiac rehabilitation, compared to standard...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $633,045 to the University of Pittsburgh to investigate the pathogenic mechanisms and therapeutic approaches for exercise intolerance in patients with Post-Acute Sequelae of COVID-19 (PASC). The key objectives are to: 1) Evaluate the predictive value of plasma angiotensin-converting enzyme 2 (ACE2) activity as a biomarker for exercise capacity in PASC patients...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $104,933 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Duke University. The grant supports research to determine the role of age-related clonal hematopoiesis of indeterminate potential (CHIP), an inflammatory biomarker, in cardiorespiratory fitness (CRF) and cardiometabolic responses to chronic exercise interventions. The project aims to evaluate whether CHIP is associated with baseline CRF and...